JPWO2020186006A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020186006A5 JPWO2020186006A5 JP2021553834A JP2021553834A JPWO2020186006A5 JP WO2020186006 A5 JPWO2020186006 A5 JP WO2020186006A5 JP 2021553834 A JP2021553834 A JP 2021553834A JP 2021553834 A JP2021553834 A JP 2021553834A JP WO2020186006 A5 JPWO2020186006 A5 JP WO2020186006A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- alkyl
- heterocyclyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816998P | 2019-03-12 | 2019-03-12 | |
| US62/816,998 | 2019-03-12 | ||
| PCT/US2020/022293 WO2020186006A1 (en) | 2019-03-12 | 2020-03-12 | Rad51 inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525069A JP2022525069A (ja) | 2022-05-11 |
| JPWO2020186006A5 true JPWO2020186006A5 (https=) | 2023-03-20 |
| JP2022525069A5 JP2022525069A5 (https=) | 2023-03-20 |
| JP7460649B2 JP7460649B2 (ja) | 2024-04-02 |
Family
ID=72422797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553834A Active JP7460649B2 (ja) | 2019-03-12 | 2020-03-12 | Ｒａｄ５１インヒビター |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11247988B2 (https=) |
| EP (1) | EP3938358B1 (https=) |
| JP (1) | JP7460649B2 (https=) |
| KR (1) | KR20210127790A (https=) |
| CN (1) | CN114072390B (https=) |
| AU (1) | AU2020235089A1 (https=) |
| BR (1) | BR112021017336A2 (https=) |
| CA (1) | CA3132987A1 (https=) |
| IL (1) | IL285889B2 (https=) |
| MX (1) | MX2021010916A (https=) |
| PH (1) | PH12021552147A1 (https=) |
| SG (1) | SG11202109399SA (https=) |
| TW (1) | TW202104198A (https=) |
| WO (1) | WO2020186006A1 (https=) |
| ZA (1) | ZA202106284B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111263756B (zh) | 2017-07-11 | 2023-05-16 | 赛泰尔治疗公司 | Rad51抑制剂 |
| SG10202107087YA (en) | 2017-09-11 | 2021-07-29 | Cyteir Therapeutics Inc | Rad51 inhibitors |
| PH12021552147A1 (en) | 2019-03-12 | 2023-01-04 | Cyteir Therapeutics Inc | Rad51 inhibitors |
| PH12021552205A1 (en) | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
| KR20220024857A (ko) | 2019-06-21 | 2022-03-03 | 사이티어 테라퓨틱스, 인크. | 췌장암의 치료를 위한 rad51 억제제의 사용 방법 |
| WO2021164746A1 (zh) * | 2020-02-19 | 2021-08-26 | 江苏先声药业有限公司 | 取代芳基类化合物 |
| WO2023078271A1 (zh) * | 2021-11-02 | 2023-05-11 | 上海旭成医药科技有限公司 | 芳香化合物、其制备方法、中间体、药物组合物和应用 |
| WO2023185831A1 (zh) * | 2022-03-29 | 2023-10-05 | 正大天晴药业集团股份有限公司 | 含有噻唑环的化合物 |
| CN114736173B (zh) * | 2022-05-24 | 2024-06-11 | 无锡捷化医药科技有限公司 | 一种3-（二氟甲基）氧杂环丁烷-3-胺盐酸盐的制备方法 |
| EP4574817A1 (en) * | 2023-12-21 | 2025-06-25 | LoQus23 Therapeutics Limited | Inhibitory compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS6230780A (ja) | 1985-04-17 | 1987-02-09 | Ss Pharmaceut Co Ltd | １，７−ナフチリジン誘導体及びこれを含有する薬剤 |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| DE69132905T2 (de) | 1990-12-06 | 2002-08-01 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Detektion von Nukleinsäuresequenzen |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| CN107007597A (zh) | 2012-05-31 | 2017-08-04 | 菲尼克斯药品股份公司 | 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途 |
| JP2017100949A (ja) | 2014-04-01 | 2017-06-08 | 大日本住友製薬株式会社 | ５員環ヘテロアリール誘導体 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| WO2016140971A1 (en) * | 2015-03-02 | 2016-09-09 | The Regents Of The University Of California | Novel rad51 inhibitors and uses thereof |
| US10442817B2 (en) * | 2015-06-04 | 2019-10-15 | Drexel University | Inhibitors of RAD52 recombination protein and methods using same |
| CN111263756B (zh) | 2017-07-11 | 2023-05-16 | 赛泰尔治疗公司 | Rad51抑制剂 |
| SG10202107087YA (en) | 2017-09-11 | 2021-07-29 | Cyteir Therapeutics Inc | Rad51 inhibitors |
| PH12021552147A1 (en) | 2019-03-12 | 2023-01-04 | Cyteir Therapeutics Inc | Rad51 inhibitors |
| PH12021552205A1 (en) | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
-
2020
- 2020-03-12 PH PH1/2021/552147A patent/PH12021552147A1/en unknown
- 2020-03-12 JP JP2021553834A patent/JP7460649B2/ja active Active
- 2020-03-12 IL IL285889A patent/IL285889B2/en unknown
- 2020-03-12 AU AU2020235089A patent/AU2020235089A1/en not_active Abandoned
- 2020-03-12 BR BR112021017336A patent/BR112021017336A2/pt not_active Application Discontinuation
- 2020-03-12 CA CA3132987A patent/CA3132987A1/en active Pending
- 2020-03-12 MX MX2021010916A patent/MX2021010916A/es unknown
- 2020-03-12 WO PCT/US2020/022293 patent/WO2020186006A1/en not_active Ceased
- 2020-03-12 US US16/816,393 patent/US11247988B2/en active Active
- 2020-03-12 CN CN202080035279.0A patent/CN114072390B/zh active Active
- 2020-03-12 TW TW109108203A patent/TW202104198A/zh unknown
- 2020-03-12 KR KR1020217032591A patent/KR20210127790A/ko not_active Abandoned
- 2020-03-12 SG SG11202109399SA patent/SG11202109399SA/en unknown
- 2020-03-12 EP EP20768883.9A patent/EP3938358B1/en active Active
-
2021
- 2021-08-30 ZA ZA2021/06284A patent/ZA202106284B/en unknown
- 2021-12-16 US US17/552,577 patent/US11932636B2/en active Active
-
2024
- 2024-01-30 US US18/427,164 patent/US20240360120A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2396267T3 (es) | Procedimiento para sintetizar compuestos útiles para el tratamiento de la hepatitis C | |
| JP2011527686A5 (https=) | ||
| JPWO2020186006A5 (https=) | ||
| JP2019519476A5 (https=) | ||
| JP2018531982A5 (https=) | ||
| JP2021514400A5 (https=) | ||
| JP2007511504A5 (https=) | ||
| JP2010504346A5 (https=) | ||
| JP2005504039A5 (https=) | ||
| JPWO2020243415A5 (https=) | ||
| JP2018531218A5 (https=) | ||
| JP2002529465A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| JP2006509842A5 (https=) | ||
| JP2021514399A5 (https=) | ||
| JP2008510719A5 (https=) | ||
| JP2024112835A5 (https=) | ||
| JP2021534254A5 (ja) | 心臓弁疾患を治療するための医薬組成物 | |
| JPWO2020219650A5 (https=) | ||
| JPWO2021003310A5 (https=) | ||
| JPWO2020264512A5 (https=) | ||
| JPWO2021026109A5 (https=) | ||
| RU2008145775A (ru) | Синтез и способы применения производных пироглутаминовой кислоты | |
| JP2005526102A5 (https=) | ||
| JPWO2020264509A5 (https=) |